| Literature DB >> 31700262 |
Yong Yook Lee1, Hwi Won Seo1, Jong-Su Kyung1, Sun Hee Hyun1, Byung Cheol Han1, Songhee Park1, Seung Ho So1, Seung Ho Lee1, Eugene C Yi2.
Abstract
BACKGROUND: Korean Red Ginseng (KRG) has been widely used as an herbal medicine to normalize and strengthen body functions. Although many researchers have focused on the biological effects of KRG, more studies on the action mechanism of red ginseng are still needed. Previously, we investigated the proteomic changes of the rat spleen while searching for molecular signatures and the action mechanism of KRG. The proteomic analysis revealed that differentially expressed proteins (DEPs) were involved in the increased immune response and phagocytosis. The aim of this study was to evaluate the biological activities of KRG, especially the immune-enhancing response of KRG.Entities:
Keywords: Immune response; Korean Red Ginseng; LC-MS/MS; Molecular signature; Proteomics
Year: 2019 PMID: 31700262 PMCID: PMC6823813 DOI: 10.1016/j.jgr.2019.05.001
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Fig. 1Schematic of the experiments: procedures and methods used for the molecular signature proteomics for the biological effects by Korean Red Ginseng. iTRAQ, isobaric tags for relative and absolute quantitation; BCA, bicinchoninic acid; KRG, Korean Red Ginseng; DAVID, Database for Annotation, Visualization and Integrated Discovery; IPA, Ingenuity Pathway Analysis.
Fig. 2Distribution of the identified proteins in the spleen and thymus in the rat. (A) Total intersection of unique proteins and peptides for all the groups. (B) Subcellular localization of the identified proteins and (C) molecule types of the identified proteins by the Ingenuity Pathway Analysis (IPA) tool.
Selected biosignature candidate proteins identified in the spleen and thymus of the rat
| Identified proteins of the spleen | Accession No. | Log2 value (mg/kg) | Identified proteins of the thymus | Accession No. | Log2 value (mg/kg) | ||||
|---|---|---|---|---|---|---|---|---|---|
| 500 | 1000 | 2000 | 500 | 1000 | 2000 | ||||
| Ifi47 protein | 0.24 | 0.24 | Myosin-4 | 1.05 | 0.21 | ||||
| Protein Mpo | A0A0G2K1A2 | 0.25 | 0.30 | Tropomyosin beta chain | 0.88 | 0.61 | |||
| Neutrophilic granule protein (predicted) | D3ZY96 | 0.26 | 0.27 | Myosin light chain 1/3, skeletal muscle isoform | 0.87 | 0.44 | |||
| Cytochrome c, somatic | 0.26 | 0.57 | Creatine kinase M-type | A0A0G2JSP8 | 0.56 | 0.38 | |||
| Hemoglobin subunit alpha-1/2 | 0.23 | 0.28 | Parvalbumin alpha | 0.33 | 0.53 | ||||
| Neutrophil gelatinase–associated lipocalin | 0.21 | 0.47 | 0.57 | Protein S100-A11 | 0.24 | 0.57 | 0.26 | ||
| Isoform 2 of adenylate kinase 2, mitochondrial | 0.37 | 0.24 | 0.71 | Niemann–Pick type C2 | F7FJQ3 | 0.23 | 0.21 | ||
| Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial | 0.22 | 0.21 | 0.24 | Myosin light chain 4 | M0R4E1 | 0.19 | 0.30 | ||
| Rano class II histocompatibility antigen, B-1 beta chain | 0.26 | 0.20 | ATP synthase-coupling factor 6, mitochondrial | 0.15 | 0.39 | ||||
| MHC class Ia protein | 0.30 | 0.22 | Rano class II histocompatibility antigen, B-1 beta chain | 0.14 | 0.21 | 0.14 | |||
| Vimentin | 0.37 | 0.24 | 0.71 | Prolargin | 0.14 | 0.16 | 0.12 | ||
| Galectin-5 | 0.45 | 0.35 | 0.55 | Protein Prkcsh | B1WC34 | 0.12 | 0.31 | 0.16 | |
| Ubiquitin-40S ribomal protein S27a | 0.20 | 0.35 | Regulator of G-protein signaling 10 | 0.10 | 0.35 | 0.17 | |||
| Histone H4 | 0.21 | 0.30 | NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial | D3ZCZ9 | 0.10 | 0.20 | 0.14 | ||
| Protein Wdr75 | A0A0G2K9A7 | 0.43 | 0.27 | Thymosin beta-4 | 0.46 | 0.19 | |||
| Arachidonate 5-lipoxygenase–activating protein | 1.88 | 0.26 | Metallothionein | D3ZHV3 | 0.45 | 0.21 | |||
| Carbonic anhydrase 1 | B0BNN3 | 0.33 | 0.26 | Myristoylated alanine-rich C-kinase substrate | 0.37 | 0.19 | |||
| Isoform A2 of Heterogeneous nuclear ribonucleoproteins A2/B1 | A7VJC2-2 | 0.23 | 0.26 | High-mobility group nucleosome binding domain 1 | 0.34 | 0.24 | |||
| RCG45246 | A0A0G2K654 | 0.51 | 0.25 | Protein Sh3bgrl3 | B2RZ27 | 0.26 | 0.28 | ||
| Carbonic anhydrase 2 | 0.26 | 0.23 | Granulin, isoform CRA_c | G3V8V1 | 0.26 | 0.20 | |||
| Protein RoBo-1 | 0.25 | 0.28 | 0.21 | MARCKS-related protein | 0.23 | 0.18 | |||
| Lysozyme f2 | F1M8E9 | 0.29 | 0.21 | Protein Rbm17 | 0.21 | 0.17 | |||
| Protein LOC684828 | M0R7B4 | 0.45 | 0.62 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 0.30 | 0.16 | |||
| Structural maintenance of chromosome protein 1A | 0.31 | 0.47 | Atrial natriuretic peptide-converting enzyme | 0.21 | 0.41 | ||||
| Barrier-to-autointegration factor | 0.34 | 0.44 | Isoform 2 of coiled-coil and C2 domain-containing protein 1A | Q66HA5-2 | 0.20 | 0.15 | |||
| Mast cell protease 9 (fragment) | 0.22 | 0.25 | D-dopachrome decarboxylase | 0.18 | 0.38 | ||||
| CRAMP (fragment) | 0.25 | 0.22 | Tropomyosin alpha-1 chain | 0.15 | 0.43 | ||||
| Chromosome segregation 1-like ( | D3ZPR0 | 0.21 | 0.21 | Protein S100-G | 0.11 | 0.49 | 0.24 | ||
| Beta-arrestin-2 | 0.20 | 0.21 | PYD and CARD domain containing | G3V8L1 | 0.10 | 0.45 | 0.21 | ||
| CD44 antigen | 0.97 | 0.30 | |||||||
| Mitochondrial import inner membrane translocase subunit Tim13 | 0.54 | 0.17 | |||||||
| Histone H2A type 1 | 0.19 | 0.27 | |||||||
| Lon protease homolog, mitochondrial | −0.22 | −0.20 | Caveolin-1 | −0.10 | −0.33 | −0.17 | |||
| Elongation factor Tu, mitochondrial | −0.21 | −0.21 | Lamin B receptor | −0.12 | −0.18 | −0.17 | |||
| ADP/ATP translocase 2 | −0.21 | −0.27 | Dihydrolipoyl dehydrogenase, mitochondrial | −0.12 | −0.19 | −0.16 | |||
| Actin, aortic smooth muscle | −0.23 | −0.21 | −0.28 | Cytochrome b-c1 complex subunit 8 | −0.13 | −0.38 | −0.34 | ||
| Isoform 2 of tropomyin beta chain | P58775-2 | −0.20 | −0.27 | −0.59 | Long-chain-fatty-acid–CoA ligase 1 | −0.14 | −0.18 | ||
| Uncharacterized protein | M0RCH6 | −0.23 | −0.28 | Fatty acid synthase | −0.15 | −0.15 | |||
| Serum albumin | −0.22 | −0.39 | Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic | −0.16 | −0.20 | ||||
| Protein SET | A0A0G2JSU3 | −0.50 | −0.43 | Myosin-6 | −0.20 | −0.15 | |||
| Apolipoprotein C–I | −0.25 | −0.46 | Succinyl-CoA ligase subunit beta (fragment) | B2RZ24 | −0.24 | −0.14 | |||
| Protein Cd209b | F1LM87 | −0.46 | −0.44 | −0.57 | Isoform 2 of Echinoderm microtubule–associated protein-like 2 | Q6P6T4-2 | −0.12 | −0.25 | −0.26 |
| Nucleolin | −0.25 | −0.25 | Signal recognition particle 54 kDa protein | −0.14 | −0.21 | −0.11 | |||
| Histone H2B | D3ZWM5 | −0.14 | −0.26 | −0.19 | |||||
| Protein Ncapg | D3ZD72 | −0.18 | −0.24 | −0.10 | |||||
| NADH dehydrogenase (ubiquinone) Fe–S protein 7 | −0.18 | −0.31 | −0.28 | ||||||
| Protein Ptges3l1 | −0.18 | −1.54 | −1.30 | ||||||
| Period circadian protein homolog 3 | G3V8D9 | −1.02 | −0.48 | −0.99 | |||||
| Proteasome activator complex subunit 2 | −0.17 | −0.14 | |||||||
| Pyruvate dehydrogenase E1 component subunit beta, mitochondrial | −0.17 | −0.17 | |||||||
| Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial | −0.18 | −0.15 | |||||||
| Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial | −0.20 | −0.15 | |||||||
| DNA helicase | D3ZP96 | −0.20 | −0.14 | ||||||
| Actin, aortic smooth muscle | −0.29 | −0.26 | |||||||
| Histone H1t | −2.32 | −2.60 | |||||||
Representatives of selected upregulated or downregulated DEPs∗ from the spleen and thymus of the KRG-treated rat model. The intensities of proteins were calculated by Scaffold Q+ within triplicate analysis
Log2 % value = Log2 fold change (FC) of the concentration among 500, 1000, and 2000 mg/kg, respectively
∗DEP (differentially expressed protein): Proteins that showed greater |log2x| values than 0.2 and 0.13 in the spleen and thymus, respectively, compared to control (0 mg/kg). These proteins exhibit the same increase or decrease tendency within at least 2 different concentrations among 500, 1000, and 2000 mg/kg (permutation test p < 0.01, Mann–Whitney test p < 0.01), except thymus proteins in gray highlighted box below (permutation test p < 0.01, Mann–Whitney test p < 0.05)
Selected DAVID and IPA functional analysis of the identified proteins
| Defense response | 1.79E-03 | IFI47, MPO, NGP | |
| Defense response to gram-positive bacterium | 6.41E-03 | CAMP, LYZ2, MPO | |
| Defense response to bacterium | 1.30E-02 | CAMP, LYZ2, MPO | |
| Cellular movement | 1.60*10−2 – 2.52*10−6 | Leukocyte migration, cell movement of cell, cell movement of granulocytes | |
| Cellular function and maintenance | 1.78*10−2 – 4.27*10−5 | Phagocytosis, engulfment of cells, cellular homeostasis | |
| Leukocyte migration | 2.194 | LYZ, ALOX5AP, CRAMP, ARRB2, LCN2, ALB | |
| Immune response of cells | 1.274 | VIM, HLA-DQB1, Cd209b, CAMP, LCN2 | |
| Infection of mammalia | −1.246 | HLA-DQB1, Cd209b, CAMP, Ifi47, LCN2 | |
| Bacterial Infections | −1.225 | LYZ, ALOX5AP, Cd209b, CAMP, LCN2 | |
| Muscle protein | 4.10E-08 | MYH4, MYL1, MYL4, PVLB, TPM2 | |
| Myosin | 6.10E-04 | MYH4, MYL1, MYL4 | |
| Actin binding | 8.10E-03 | MYH4, MARCKS, MARCKS1, TMSB4X, TPM2 | |
| Lipid metabolism | 1.25*10−2 – 1.72*10−8 | accumulation of lipid, synthesis of fatty acid | |
| Small molecule biochemistry | 1.25*10−2 – 1.72*10−8 | metabolism of ATP, synthesis of acetyl-coenzyme A | |
| Immune response of cells | 1.699 | PYCARD, CC2D1A, PSME2, CD44, CD38, HLA-DQB1 | |
| Immune response of leukocytes | 1.432 | PYCARD, PSME2, CD44, CD38, HLA-DQB1 | |
| Accumulation of lipid | −1.690 | SDHB,CAV1,CD44,ACSL1,NPC2 | |
| Viral Infection | −1.474 | HIST2H2AA3/HIST2H2AA4, RBM17, PVALB, CKM, NDUFS7, PYCARD, PSME2, HLA-DQB1, HIST1H2BN, PER3, ACTA2, CD44, CAV1, CD38, FGA, ACSL1 | |
Functional annotations of proteins in Table 1 were obtained from DAVID (https://david.ncifcrf.gov/home.jsp) and further detailed analysis was performed with IPA. P-value, which is a probability of associated molecules from experimental data sets, was also calculated by DAVID and IPA, respectively. Z-score is a statistical measure of the match between expected relations and observed protein expression. The Z-score indicates overall increase (+) or decrease (−) of identified proteins in pathway database of IPA
DAVID, Database for Annotation, Visualization and Integrated Discovery; IPA, Ingenuity Pathway Analysis.
Fig. 3Analysis of immune-related activation components. (A) Selected increased immunological functions and (B) function related to activating immune cells in the spleen and (C) in the thymus by KRG. Orange color, the biological process or disease is trending toward an increase. Blue color, the biological process or disease is trending toward a decrease. The values represent the log2 fold change. KRG, Korean Red Ginseng.
Fig. 4Western blot validation of the representative biosignature candidates in the rat spleen. Western blot bands were quantified by Image J (NIH), and the protein levels of the spleen (normalized to actin) from the experiment were expressed as an arbitrary unit. (Quantitative analysis n = 5) HLA-DQB1/B2, LCN2, vimentin, MPO, and CRAMP were tested. Actin was used as a loading control (See Supplemental Fig. 1).